Prostatic Neoplasms Clinical Trials in Philadelphia, Pennsylvania

3 studies are recruiting for prostatic neoplasms in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agen…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Fox Chase Cancer Center ( Site 0076), Philadelphia, Pennsylvania
    Locations
    330 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06136650 on ClinicalTrials.gov

  2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Perelman Center for Advanced Medicine ( Site 0067), Philadelphia, Pennsylvania
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  3. A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

    The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania
    Locations
    19 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT06095089 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.